Midterm results of transventricular mitral valve repair: Single-center experience

Neochord DS1000 system versus conventional mitral valve repair for correction of mitral regurgitation due to prolapse of the posterior leaflet

“…They identified 88 pairs of patients with similar clinical profiles except for functional class which was worse in the Neochord group. The patients in this study were younger than in most reports on longitudinal outcomes of mitral valve repair [ 2 , 3 ]. The chose patients’ survival as the primary endpoint of the study but since a propensity score analysis was used to compensate for differences in age and comorbidities, this does not seem rational.…”

“…Hopefully, this randomized clinical trial will help us to determine the usefulness of this device. Based on D'Onofrio and colleagues [ 1 ] experience and on that of others [ 3 ], I am not sure this device should be used in any patient who can have conventional mitral valve repair. There are, however, patients with posterior leaflet prolapse with intractable heart failure that would not tolerate a median sternotomy or even a right mini-thoracotomy with cardiopulmonary bypass and, perhaps, they should be considered for this device but only after excluding the feasibility of a transcatheter Mitraclip™ (Abbott Laboratories, Chicago, IL, USA), which is likely to provide better and safer outcomes [ 5 ].…”

Commentary: Striking the right chord

“…Lawrence M. Wei, MD, and Vinay Badhwar, MD In this issue of the Journal, Budra and colleagues 1 report the first mid-term results of transventricular mitral valve (MV) repair with the NeoChord DS1000 Artificial Chordae Delivery System (NeoChord, St Louis Park, Minn). This device aims to treat primary mitral regurgitation (MR) by implantation of expanded polytetrafluoroethylene (ePTFE) sutures to prolapsing or flail MV leaflet segments via a transapical approach on the beating heart.…”

Actual perspective on off‐pump transapical artificial chord implantation

“…This relatively new device, 1 follows the footsteps of Neochord (Neochord, Inc.) and Harpoon (Edwards Lifesciences) and permits the positioning of polytetrafluoroethylene (ePTFE) artificial chordae through a transapical off‐pump ventricular access. The efficacy and safety of this solution have already been demonstrated mainly thanks to the worldwide expansion of the Neochord experience 2–26 …”